Novartis [h1n1] going "Universal"
@revellanotvanella (4033)
United States
August 14, 2009 5:25am CST
March 1996: Sandoz and Ciba Gelgy announce merger plans
December 1996:
Formation of NOVARTIS
July 2000: Novartis one of the first companies to sign UN Global Compant
May 2002: Creation of Novartis Institues for BioMedical Research for Pharmaceuticals research
August 2005: Acquisition of OTC brands from Bristol Myers Squibb
April 2006: Entry into human vaccines through Chiron acquisition
February: Opening of Novartis Vaccines Institute for Global Health
APRIL/July 2008: Rights to acquire majority stake in Alcon, a world leader in eye care, from Nestle, initial 25% stake purchased in July
Chart:NOVARTIS IS NOW A LEADING HEALTHCARE COMPANY NOVARTIS GROUP ANNUAL REPORT,'08
Bioterrorism Act (BTA) Signed by Bush June 12, 2002
Title I is its establishment of the Strategic National Stockpile (SNS). The SNS took the place of the National Pharmaceutical Stockpile (NPS) which was established in 1999 by the department of HHS. The new stockpile is a stash of emergency vaccines, medicines and medical supplies available in case of an emergency. The SNS can also be tapped if a natural disaster occurs.
The BTA has also set up "push packages" in guarded warehouses all across the country. These packages contain emergency vaccines and treatments for the most likely biological agents and can be distributed to any location in the United States within 12 hours of being ordered by the CDC.
federal agencies work together under the BTA:
* The Food and Drug Administration (FDA)
* Centers for Disease Control and Prevention (CDC)
* U.S. Department of Agriculture (USDA)
* Animal and Plant Health Inspection Service (APHIS)
* Environmental Protection Agency (EPA)
* Federal Bureau of Investigation (FBI)
* Department of Homeland Security (DHS)
* Department of Health and Human Services (HHS)
* U.S. Customs and Border Protection (CBP)
------------------------------------------------------------------------------------------
Novartis HEALTHCARE PORTFOLIO OVERVIEW
We believe our portfolio best meets the varied and often complex needs of patients and societies.
Novartis is positioned to lead in innovation, partnet with others and offer solutions to patients across
a broad healthcare spectrum. In addition, a diverse portfolio reduces financial risk, bringing greater value to
those who invest in our company.
Novartis has been transformed since its creation in 1996-when only 45% of net sales came from healthcare--into a
leader focused on fast growing areas of healthcare.
----------------------------------------------------------------------------------------
Novartis is currently organized into 4 divisions:
--pharmaceuticals: Innovative patent-protected medicines
--Vaccines and Diagnostics: Human vaccines and diagnostic tools to protect against
life threatening diseases
--Sandoz: Generic pharmaceuticals that replace branded medicines after patent
expiry and free up funds for innovative medicines
--Consumer Health: Readily available products that enable healthy lifestyle choice:
OTC (Over-the-Counter), Animal Health and CIBA Vision
February 5, 1976, an Army recruit told his drill instructor at Fort Dix that he "felt tired and weak but not sick enough to see military medics"--Within 24 hours, 19-year-old Pvt. David Lewis of Ashley Falls, Mass., was dead, killed by an influenza not seen since the plague of 1918-19.
Two weeks after the recruit's death, health officials disclosed to America that something called "swine flu" had killed Lewis and hospitalized four of his fellow soldiers at the Army base in Burlington County.[http://www.capitalcentury.com/1976.html]
[i]In a disturbing new projection, health officials say up to 40 percent of Americans could get swine flu this year and next and several hundred thousand could die without a successful vaccine campaign and other measures.
The estimates by the Centers for Disease Control and Prevention are roughly twice the number of those who catch flu in a normal season and add greater weight to hurried efforts to get a new vaccine ready for the fall flu season.[/i][sfgate.com]
Novartis applied for just a patent on Nov. 4, 2005, and the U.S. Patent Office accepted this application and granted US 20090047353A1 for a "Split Influenza Vaccine with Adjuvants" on February 19, 2009
-----------------------------------------------------------------------------------------
Novartis' Patent Case in India
http://pubs.acs.org/cen/news/87/i28/8728notw5.html
"India's Intellectual Property Appellate Board has ruled that Novartis' patent on the cancer drug Gleevec is not valid in that country. The decision marks the third time in four years that Novartis has failed in attempts to legally enforce its patent on the drug..."
"..Concurring with earlier decisions, the board ruled that Gleevec is nothing but a crystal modification of an older drug that was initially patented in 1993 and therefore does not qualify as a new invention. Under patenting rules that India began implementing in 2005, only drugs invented after 1995 are eligible for patent protection."
"Health activists such as Doctors Without Borders and India's Cancer Patient Aid Association see the Gleevec case in terms of the impact it could have on drug pricing. A win for Novartis would force India's generic pharmaceutical companies to stop producing and exporting their own versions of Gleevec and, more important, dissuade them from launching generic versions of other drugs in the future."
-------------------------------------------------------------------------------------------
Novartis (NYSE: NVS) is one of the largest pharmaceutical companies in the world, with annual sales of $42.6 billion. While Novartis produces medications for many diseases, cancer and cardiovascular medications make up the bulk of sales. These medications include blockbuster drugs Gleevec and Diovan, which will benefit from the demographic realities of an aging US population that is more susceptible to cancer or cardiovascular problems. In addition to their current drugs, Novartis has one of the strongest pipelines in the pharmaceutical industry, with over 50 new products set to premier in the next several years.
Novartis's oncology and cardiovascular franchises each earned over $5 billion in sales in 2007 with growth in the double digits.
Novartis is moving more and more towards biologics, compounds that mimic substances in the body. Biologics are a sound investment for drug companies because they are generally seen as more resistant to generic competition due to the fact that they are difficult to make/copy.
Novartis has a wide variety of products, including pharmaceuticals, vision products, baby foods(sold Gerber 2007?), and animal medications. This diversity insulates Novartis from market fluctuations and makes for an overall more stable corporation.
Sandoz is the largest generic manufacturer under a major pharmaceutical company.[1] This investment in the generic market allows Novartis to be somewhat insulated from patent expiration.
Novartis has fewer drugs up for patent expiration in the next 5 years than other competing companies (Merck, Bristol-Meyer, Pfizer)
Net sales up 5% (+1% in local currencies) to USD 7.6 billion. Improving performance in many markets--led by 13% lc growth in Central and Easter Europe and leading position in Russia-largely offset by a 10% decline
in the United States from lack of new product launches in 2008.[charles Schwab]
----------------------------------------------------------------------------------------
Formation of NOVARTIS
July 2000: Novartis one of the first companies to sign UN Global Compant
May 2002: Creation of Novartis Institues for BioMedical Research for Pharmaceuticals research
August 2005: Acquisition of OTC brands from Bristol Myers Squibb
April 2006: Entry into human vaccines through Chiron acquisition
February: Opening of Novartis Vaccines Institute for Global Health
APRIL/July 2008: Rights to acquire majority stake in Alcon, a world leader in eye care, from Nestle, initial 25% stake purchased in July
Chart:NOVARTIS IS NOW A LEADING HEALTHCARE COMPANY NOVARTIS GROUP ANNUAL REPORT,'08
Bioterrorism Act (BTA) Signed by Bush June 12, 2002
Title I is its establishment of the Strategic National Stockpile (SNS). The SNS took the place of the National Pharmaceutical Stockpile (NPS) which was established in 1999 by the department of HHS. The new stockpile is a stash of emergency vaccines, medicines and medical supplies available in case of an emergency. The SNS can also be tapped if a natural disaster occurs.
The BTA has also set up "push packages" in guarded warehouses all across the country. These packages contain emergency vaccines and treatments for the most likely biological agents and can be distributed to any location in the United States within 12 hours of being ordered by the CDC.
federal agencies work together under the BTA:
* The Food and Drug Administration (FDA)
* Centers for Disease Control and Prevention (CDC)
* U.S. Department of Agriculture (USDA)
* Animal and Plant Health Inspection Service (APHIS)
* Environmental Protection Agency (EPA)
* Federal Bureau of Investigation (FBI)
* Department of Homeland Security (DHS)
* Department of Health and Human Services (HHS)
* U.S. Customs and Border Protection (CBP)
------------------------------------------------------------------------------------------
Novartis HEALTHCARE PORTFOLIO OVERVIEW
We believe our portfolio best meets the varied and often complex needs of patients and societies.
Novartis is positioned to lead in innovation, partnet with others and offer solutions to patients across
a broad healthcare spectrum. In addition, a diverse portfolio reduces financial risk, bringing greater value to
those who invest in our company.
Novartis has been transformed since its creation in 1996-when only 45% of net sales came from healthcare--into a
leader focused on fast growing areas of healthcare.
----------------------------------------------------------------------------------------
Novartis is currently organized into 4 divisions:
--pharmaceuticals: Innovative patent-protected medicines
--Vaccines and Diagnostics: Human vaccines and diagnostic tools to protect against
life threatening diseases
--Sandoz: Generic pharmaceuticals that replace branded medicines after patent
expiry and free up funds for innovative medicines
--Consumer Health: Readily available products that enable healthy lifestyle choice:
OTC (Over-the-Counter), Animal Health and CIBA Vision
February 5, 1976, an Army recruit told his drill instructor at Fort Dix that he "felt tired and weak but not sick enough to see military medics"--Within 24 hours, 19-year-old Pvt. David Lewis of Ashley Falls, Mass., was dead, killed by an influenza not seen since the plague of 1918-19.
Two weeks after the recruit's death, health officials disclosed to America that something called "swine flu" had killed Lewis and hospitalized four of his fellow soldiers at the Army base in Burlington County.[http://www.capitalcentury.com/1976.html]
[i]In a disturbing new projection, health officials say up to 40 percent of Americans could get swine flu this year and next and several hundred thousand could die without a successful vaccine campaign and other measures.
The estimates by the Centers for Disease Control and Prevention are roughly twice the number of those who catch flu in a normal season and add greater weight to hurried efforts to get a new vaccine ready for the fall flu season.[/i][sfgate.com]
Novartis applied for just a patent on Nov. 4, 2005, and the U.S. Patent Office accepted this application and granted US 20090047353A1 for a "Split Influenza Vaccine with Adjuvants" on February 19, 2009
-----------------------------------------------------------------------------------------
Novartis' Patent Case in India
http://pubs.acs.org/cen/news/87/i28/8728notw5.html
"India's Intellectual Property Appellate Board has ruled that Novartis' patent on the cancer drug Gleevec is not valid in that country. The decision marks the third time in four years that Novartis has failed in attempts to legally enforce its patent on the drug..."
"..Concurring with earlier decisions, the board ruled that Gleevec is nothing but a crystal modification of an older drug that was initially patented in 1993 and therefore does not qualify as a new invention. Under patenting rules that India began implementing in 2005, only drugs invented after 1995 are eligible for patent protection."
"Health activists such as Doctors Without Borders and India's Cancer Patient Aid Association see the Gleevec case in terms of the impact it could have on drug pricing. A win for Novartis would force India's generic pharmaceutical companies to stop producing and exporting their own versions of Gleevec and, more important, dissuade them from launching generic versions of other drugs in the future."
-------------------------------------------------------------------------------------------
Novartis (NYSE: NVS) is one of the largest pharmaceutical companies in the world, with annual sales of $42.6 billion. While Novartis produces medications for many diseases, cancer and cardiovascular medications make up the bulk of sales. These medications include blockbuster drugs Gleevec and Diovan, which will benefit from the demographic realities of an aging US population that is more susceptible to cancer or cardiovascular problems. In addition to their current drugs, Novartis has one of the strongest pipelines in the pharmaceutical industry, with over 50 new products set to premier in the next several years.
Novartis's oncology and cardiovascular franchises each earned over $5 billion in sales in 2007 with growth in the double digits.
Novartis is moving more and more towards biologics, compounds that mimic substances in the body. Biologics are a sound investment for drug companies because they are generally seen as more resistant to generic competition due to the fact that they are difficult to make/copy.
Novartis has a wide variety of products, including pharmaceuticals, vision products, baby foods(sold Gerber 2007?), and animal medications. This diversity insulates Novartis from market fluctuations and makes for an overall more stable corporation.
Sandoz is the largest generic manufacturer under a major pharmaceutical company.[1] This investment in the generic market allows Novartis to be somewhat insulated from patent expiration.
Novartis has fewer drugs up for patent expiration in the next 5 years than other competing companies (Merck, Bristol-Meyer, Pfizer)
Net sales up 5% (+1% in local currencies) to USD 7.6 billion. Improving performance in many markets--led by 13% lc growth in Central and Easter Europe and leading position in Russia-largely offset by a 10% decline
in the United States from lack of new product launches in 2008.[charles Schwab]
----------------------------------------------------------------------------------------No responses
